Scrip
US panel baulks at broader use of AstraZeneca's Seroquel XR
09 April 2009
Sue Sutter
Please Login to read the full article.
09 April 2009
Sue Sutter
Citing safety concerns, a US
FDA advisory panel baulked at approving
AstraZeneca's Seroquel XR (quetiapine fumarate extended-release) for monotherapy use in major depressive disorder (MDD) and generalised anxiety disorder (GAD), but said the atypical antipsychotic's risk profile is acceptable...
Please Login to read the full article.
RELATED CONTENT
NEWS
- US panel backs paediatric use of Seroquel and Zyprexa, but splits on Geodon
- US panel review for Seroquel paediatric indications
- Seroquel collects more approvals, and a complete response letter, from the US FDA
- Lundbeck's antipsychotic Serdolect safe for some patients, US panel says
COMMENT
Other Informa Comment
EVENTS
Today
Cambridge, UK
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
